Wang Rui, Gao Dong, Zhou Yin, Chen Lu, Luo Bin, Yu Yanrong, Li Hao, Hu Jiawei, Huang Qiren, He Ming, Peng Weijie, Luo Dan
School of Pharmaceutics, Jiangxi Medical College, Nanchang University, Bayi Road 461, Nanchang, Jiangxi Province, 330006, PR China.
School of Pharmaceutics, Jiangxi Medical College, Nanchang University, Bayi Road 461, Nanchang, Jiangxi Province, 330006, PR China; Jiangxi Academy of Medical Science, Bayi Road 461, Nanchang, Jiangxi Province, 330006, PR China.
J Steroid Biochem Mol Biol. 2017 Nov;174:276-283. doi: 10.1016/j.jsbmb.2017.10.008. Epub 2017 Oct 10.
Diabetic Mellitus is a risk factor for osteoporosis. It has been suggested that altered estrogen or estrogen receptor α/β (ERα/β) signaling may be involved in diabetic osteoporosis. The present study is to investigate the effects of high glucose on ERα/β signaling in osteoblastic MC3T3-E1 and how the altered signaling of ERα/β affect osteoblastic bone formation. ERα/β signaling was demonstrated as ERα/β protein expression (Western Blotting) and ER transcription activity (Luciferase Reporter assays). Proliferation (WSK-1 assaying), differentiation (ALP staining) and mineralization (Alizalard Red staining) of MC3T3-E1 were examined to evaluate bone formation function. It has been found that high glucose increased ERα/β expression dose-dependently and time-dependently, but high glucose (33mM) decreased ERα transcription activity. 17β-estradiol increased the ERα/β expression dose-dependently in normal medium, but decreased the ERα/β expression dose-dependently in medium with high glucose (33mM). High glucose decreased bone formation and also decreased the osteogenic effects of 17β-estradiol (10M). High glucose decreased β-catenin expression dose-dependently and time-dependently. LiCl, an inhibitor of β-catenin degradation, decreased ERα expression but increased ERα transcription activity. When compared with high glucose treatment, LiCl (5mM) increased ALP activity and calcified nodes. Besides, high glucose also decreased the protein expression PI-3K, pAKT/AKT, GSK-3β. In conclusion, the present study suggested that high glucose may impair ERα transcription activity by inhibiting β-catenin signaling in osteoblastic MC3T3-E1, leading decreased bone formation ligand-dependently or ligand-independently.
糖尿病是骨质疏松症的一个风险因素。有人提出,雌激素或雌激素受体α/β(ERα/β)信号改变可能与糖尿病性骨质疏松症有关。本研究旨在探讨高糖对成骨细胞MC3T3-E1中ERα/β信号的影响,以及ERα/β信号改变如何影响成骨细胞的骨形成。ERα/β信号通过ERα/β蛋白表达(蛋白质免疫印迹法)和ER转录活性(荧光素酶报告基因检测)来证明。检测MC3T3-E1的增殖(WSK-1检测)、分化(碱性磷酸酶染色)和矿化(茜素红染色)以评估骨形成功能。研究发现,高糖剂量和时间依赖性地增加ERα/β表达,但高糖(33mM)降低ERα转录活性。17β-雌二醇在正常培养基中剂量依赖性地增加ERα/β表达,但在高糖(33mM)培养基中剂量依赖性地降低ERα/β表达。高糖降低骨形成,也降低17β-雌二醇(10M)的成骨作用。高糖剂量和时间依赖性地降低β-连环蛋白表达。β-连环蛋白降解抑制剂氯化锂降低ERα表达,但增加ERα转录活性。与高糖处理相比,氯化锂(5mM)增加碱性磷酸酶活性和钙化结节。此外,高糖还降低蛋白表达PI-3K、pAKT/AKT、GSK-3β。总之,本研究表明,高糖可能通过抑制成骨细胞MC3T3-E1中的β-连环蛋白信号来损害ERα转录活性,导致骨形成配体依赖性或配体非依赖性降低。